Point72 Asset Management’s BioMarin Pharmaceuticals BMRN Stock Holding History

Point72 Asset Management’s Portfolio BMRN Stock Details BMRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$5.65M	Buy	+100,000	New	+$5.83M	0.01%	1623
2025 Q1	–	Sell	-300,000	Closed	-$19.7M	–	2059
2024 Q4	$19.7M	Hold	300,000	–	–	0.04%	460
2024 Q3	$21.1M	Buy	+300,000	New	+$25.1M	0.05%	402
2022 Q2	–	Sell	-84,900	Closed	-$6.55M	–	1409
2022 Q1	$6.55M	Buy	+84,900	New	+$7.1M	0.03%	625
2018 Q1	–	Sell	-883,400	Closed	-$78.8M	–	948
2017 Q4	$78.8M	Buy	883,400 +564,400	+177%	+$49.1M	0.34%	71
2017 Q3	$29.7M	Buy	+319,000	New	+$28.2M	0.13%	190

Other funds holding BMRN

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Point72 Asset Management's BMRN Position: Q1 2026 in Review

Point72 Asset Management increased its BioMarin Pharmaceuticals (BMRN) stake by 173% in Q1 2026, buying an estimated $44.3M and bringing the position to 1,199,206 shares worth $67.7M. The position accounts for 0.09% of the portfolio, ranked #272.

Point72 Asset Management first reported a position in BMRN in Q2 2014 and has held it in 30 quarters since. The position peaked at $118M in Q1 2024. 554 funds tracked by Wall St. Rank hold BMRN as of Q1 2026.

Point72 Asset Management held 1,199,206 shares of BioMarin Pharmaceuticals worth $67.7M as of Q1 2026.
Point72 Asset Management bought 760,389 BioMarin Pharmaceuticals shares in Q1 2026, an estimated $44.3M.
BioMarin Pharmaceuticals made up 0.09% of Point72 Asset Management's portfolio in Q1 2026, its #272 holding.
Point72 Asset Management first reported a position in BioMarin Pharmaceuticals in Q2 2014 and has held it in 30 quarters since.
Point72 Asset Management's BioMarin Pharmaceuticals position peaked at $118M in Q1 2024.
554 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q1 2026.

Based on Point72 Asset Management's 13F filing for Q1 2026, filed 15 May 2026.